Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that it included the first patient in its Phase IV registry evaluating the use of inhaled Inomax nitric oxide gas for premature neonates compared to term and near-term newborns.
Inomax, which has FDA approval, is designed to boost oxygenation and lessen the need for extracorporeal membrane oxygenation in term and near-term neonates with hypoxic respiratory failure linked to pulmonary hypertension.
Get the full story at our sister site, Drug Delivery Business News.
The post Mallinckrodt enrolls first infant in registry for inhaled nitric oxide gas appeared first on MassDevice.
from MassDevice http://ift.tt/2ugFYVd
Cap comentari:
Publica un comentari a l'entrada